It was reported that pharmacologically-enhanced Nrf2 activity by Oltipraz prevented insulin resistance and attenuated the HFD effect on glucose disposal, and reduced HFD-induced obesity [35], further demonstrated that Nrf2 played negative roles in the regulation of lipid metabolism. The gene discussed is NFE2L2; the disease is obesity due to melanocortin 4 receptor deficiency.